Dublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Treatment (GBM) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Glioblastoma Multiforme Treatment (GBM) was estimated at US$2.9 Billion in 2023 and is projected to reach US$4.8 Billion by 2030, growing at a CAGR of 7.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. 
Glioblastoma multiforme (GBM), one of the most aggressive and fatal forms of brain cancer, presents unique treatment challenges due to its rapid growth, complex cellular structure, and resistance to conventional therapies. GBM tumors are highly invasive, spreading quickly into surrounding brain tissues and making complete surgical removal difficult.
The growth in the GBM treatment market is driven by several factors, including the unmet need for effective therapies, advancements in targeted and immunotherapies, and robust clinical trial activity. The high recurrence rate and poor prognosis associated with GBM have intensified the search for new treatments, driving pharmaceutical investment and research.
Breakthroughs in targeted and immune-based therapies offer promising alternatives to traditional treatments, while regulatory support for clinical trials is accelerating the introduction of novel treatments. Additionally, patient advocacy and pharmaceutical collaborations are sustaining this momentum, positioning the GBM treatment market for significant growth as it addresses a critical therapeutic gap.
How Are Targeted Therapies and Immunotherapies Revolutionizing GBM Treatment?
Advancements in targeted therapies and immunotherapies are offering new hope for GBM treatment. Targeted therapies, such as tyrosine kinase inhibitors, specifically target cancer cells, potentially reducing damage to surrounding healthy brain tissues. Immunotherapies, including CAR-T cell therapy and oncolytic virus therapy, harness the body's immune system to identify and attack cancer cells, showing promise in managing GBM's aggressive behavior. These therapies are particularly valuable in recurrent GBM cases, where traditional therapies often fall short. While these treatments are still in various stages of research and clinical trials, they are helping to shape a more personalized approach to GBM treatment.
What Role Do Clinical Trials Play in Advancing GBM Therapies?
Clinical trials are crucial in developing effective GBM therapies, as they provide a structured pathway to test the safety and efficacy of novel treatments. Numerous clinical trials are underway to evaluate new drug combinations, immunotherapy protocols, and innovative delivery methods, such as intracranial drug delivery systems that bypass the blood-brain barrier.
The FDA and other regulatory bodies are also granting special designations like "Orphan Drug" status to certain GBM drugs, fast-tracking their development. Patient advocacy groups and pharmaceutical partnerships are funding these clinical trials, supporting advancements in a field where few treatment options currently exist.
Key Questions Answered:
- How is the Global Glioblastoma Multiforme Treatment (GBM) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players in the Global Glioblastoma Multiforme Treatment (GBM) Market such as Amneal Pharmaceuticals, Inc., CARsgen Therapeutics, Epitopoietic Research Corporation (ERC.SA.), F. Hoffmann-La Roche AG, GBM Communications and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Scope of the Study
- Treatment (Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy)
- End-Use (Hospitals, Clinics, Ambulatory Surgery Centers)
- World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 192 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $2.9 Billion |
| Forecasted Market Value (USD) by 2030 | $4.8 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of COVID-19 and a Looming Global Recession
- Glioblastoma Multiforme Treatment (GBM) - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
MARKET TRENDS & DRIVERS
- Rising Incidence of Glioblastoma Driving Treatment Needs
- Technological Advancements in Tumor Imaging and Diagnosis
- Expansion of Precision Medicine in Glioblastoma Treatment
- Increasing Adoption of Targeted Therapy in Cancer Treatment
- Growth in Research for Immunotherapy in Glioblastoma
- Higher Demand for Combination Treatment Approaches
- Development of New Delivery Mechanisms for GBM Therapies
- Growing Use of AI in Glioblastoma Treatment Planning
- Expansion of Clinical Trials Focused on Novel GBM Treatments
- Increased Funding for Brain Cancer Research
- Surge in Demand for Non-Invasive Monitoring Solutions
- Interest in Personalized and Genomic Medicine for GBM
FOCUS ON SELECT PLAYERS:Some of the 33 companies featured in this Global Glioblastoma Multiforme Treatment (GBM) Market report include
- Amneal Pharmaceuticals, Inc.
- CARsgen Therapeutics
- Epitopoietic Research Corporation (ERC.SA.)
- F. Hoffmann-La Roche AG
- GBM Communications
- GBM Digital Technologies
- ImmunoCellular Therapeutics Ltd.
- Ivy Foundation
- Sapience Therapeutics
- SonALAsense
For more information about this report visit https://www.researchandmarkets.com/r/mqufb2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
